Danuta Jeziorska, Nucleome Therapeutics CEO

Drug dis­cov­ery biotech look­ing in­to the ‘dark’ re­gions of the hu­man genome picks up a $40M+ Se­ries A

While the com­bo of ma­chine learn­ing and drug dis­cov­ery has man­aged to rake in a lot of cap­i­tal for com­pa­nies this year, one biotech is look­ing to the dark side of the genome to stand out.

Nu­cle­ome Ther­a­peu­tics, a UK-based com­pa­ny found­ed in 2019 and spun off from Ox­ford Uni­ver­si­ty, is seek­ing to cre­ate pre­ci­sion med­i­cines by de­cod­ing “dark mat­ter” from the hu­man genome to find tar­gets no one else has gone af­ter. The com­pa­ny has now gar­nered a £37.5 mil­lion ($42.4 mil­lion) Se­ries A to ad­vance its dis­ease pro­grams and build out its plat­form.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.